Industry applications

BostonGene’s AI-powered platform integrates molecular and immune profiling techniques to comprehensively analyze tumor, microenvironment, and host immunity. Benefit from fast, accurate results in a CLIA-certified, CAP-accredited, and New York State-approved environment. Save time and resources with BostonGene’s streamlined investigational process.
Target analysis
Advanced bioinformatics solutions for big data omics (genomics, transcriptomics, and proteomics) analysis evaluates potential disease-relevant drug target candidates.
Mechanism of action analysis
Integration of multi-omics data, such as DNA sequencing, RNA sequencing, and proteomics, identifies pathways affected by the drug and predicts the downstream effects of the drug on various cellular processes.
Biomarker discovery
Combining BostonGene’s bioinformatics analysis pipeline with a proprietary sample preparation process, integrated genomic and transcriptomic sequencing, and advanced flow and imaging technologies enables the identification and validation of biomarkers for diagnosis, prognosis, and therapeutic response.
Adverse effects analysis
Immunoprofiling technology captures immune system changes preceding the development of immune-related adverse events (irAE), categorizes patients into risk groups for severe irAE, and identifies immune-modulating treatment options to alleviate irAE's severe complications.
Clinical trial support and patient stratification
Four CLIA-certified/CAP-accredited platforms can assist you in ensuring that the trial population is well-defined and representative of the targeted patient population.
Selection of new indication
Identification of potential new drug indications based on a patient’s tumor molecular profile provides insight into the efficacy of the drug in other cancer types.
Tumor microenvironment (TME) classification
Transcriptomic-based TME classification provides valuable insights for comprehensive characterization of the tumor and its microenvironment.
Companion diagnostics development
Development of custom assays for CDx testing provides support from biomarker identification to final FDA approval.
Early response monitoring
Advanced molecular profiling technologies help monitor treatment responses and identify potential resistance mechanisms, enabling timely intervention and optimization of therapy.
Disease pathology study
Custom IHC and H&E analysis of tissue samples provides comprehensive insights into disease pathology and potential treatment response.